Re­mote FDA drug in­spec­tions: New draft guid­ance spells out post-pan­dem­ic specifics

Last year
FDA+
Manufacturing

‘Ex­cit­ed to be back’: Roche’s se­quel to failed Alzheimer’s an­ti­body looks promis­ing in ear­ly study

Last year
R&D

No­var­tis re­fresh­es Kisqali metasta­t­ic breast can­cer cam­paign with mes­sage to both ‘live longer and live well’

Last year
Pharma
Marketing

GSK says RSV vac­cine trig­gered im­mune re­sponse in adults as young as 50 years old

Last year
Pharma

GHMC health­care net­work ex­pands south, part­ners with Mex­i­co-based agency

Last year
Pharma
Marketing

NIH nom­i­nee Mon­i­ca Bertag­nol­li clears Sen­ate pan­el with bi­par­ti­san sup­port de­spite Sanders’ drug pric­ing qualms

Last year
People
Pharma

Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al; Nykode’s $45M place­ment; Ideaya’s post-ES­MO of­fer­ing

Last year
News Briefing

BioX­cel says in­de­pen­dent au­dit of Alzheimer’s study found mis­con­duct did not im­pact da­ta re­li­a­bil­i­ty

Last year
R&D

Bio­gen touts glimpses of ef­fi­ca­cy in ear­ly study of tau-low­er­ing drug

Last year
R&D

Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Last year
R&D
Pharma

How Bris­tol My­er­s' buy­out of­fer for Mi­rati dwin­dled by bil­lions of dol­lars

Last year
Deals

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Last year
China
Outsourcing

DermBiont rais­es $35.2M Se­ries B to ad­vance two der­ma­to­log­i­cal drugs through PhII

Last year
Financing

Gri­fol­s' Alzheimer’s vac­cine ap­pears safe, but ef­fi­ca­cy un­clear, in PhII study

Last year
R&D

FDA ex­pect­ed to de­cide on As­traZeneca's self-ad­min­is­tered flu vac­cine next quar­ter

Last year
Pharma
FDA+

Sam­sung adds an­oth­er Lu­cen­tis in­ter­change­able biosim­i­lar to the mix

Last year
Pharma
FDA+

Bio­gen, GSK, No­vo Nordisk and five oth­er bio­phar­mas land on an­nu­al list of best in­ven­tions for 2023

Last year
Pharma
Marketing

Up­dat­ed: Form 483 for UCB's Swiss site notes de­fi­cien­cies in qual­i­ty con­trol op­er­a­tions

Last year
Manufacturing

Am­gen to cut 350 staffers fol­low­ing $28B Hori­zon takeover

Last year
People
Pharma

Sanders goes af­ter NIH for grant­i­ng ex­clu­sive patent for po­ten­tial can­cer ther­a­py

Last year
Pharma
FDA+

Mer­ck KGaA rais­es aware­ness for smol­der­ing MS symp­toms that cause pa­tients to 'un­rav­el'

Last year
Pharma
Marketing

How No­vo Nordisk’s Ry­bel­sus went from pan­dem­ic washout to block­buster, and what’s next for oral weight loss

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Fishawack re­brands as Avalere Health; BMS, Gilead, Am­gen re­up clin­i­cal di­ver­si­ty pro­gram

Last year
Pharma
Marketing

Bris­tol My­ers pays $350M up­front for rights to heart drug Camzyos in Asia

Last year
Deals
First page Previous page 257258259260261262263 Next page Last page
A service from the Financial Times